Saturday, October 16 2021

TipRanks

Verve Therapeutics: Battling Bad Cholesterol with Single Treatment

Are you looking for a biotech stock with growth potential? Verve Therapeutics (VERV) could be of interest to you. The stock appears expensive, as it has crushed the benchmark index so far this year, growing over 120%. Thus, I am bullish on the stock, but only if the price were lower. Headquartered in Cambridge, Massachusetts, Verve Therapeutics is a biotech developer of innovative treatments for cardiovascular disease patients. The company’s lead treatment candidate is called VERVE-101. It is a

Source: Yahoo Sports

Previous

Yankees activate Corey Kluber, move Zack Britton to 60-day IL

Next

Celtics Lab 64: Grading the Boston Celtics’ offseason with SI’s Michael Pina

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Pro Sports Media

Trending Now

Warriors’ Jonathan Kuminga to miss preseason finale with injury

Jonathan Kuminga will not play in the Golden State Warriors‘ preseason finale on Friday versus the Portland Trail Blazers due to a right patellar tendon strain. Kuminga suffered the injury on Oct. 6 in the fourth quarter against the Denver Nuggets. The exact play when it occurred is not known but he left the game […]

Read More

Giants hurt by odd MLB rule in controversial NLDS loss vs. Dodgers

Odd MLB rule played role in Giants’ controversial NLDS loss originally appeared on NBC Sports Bayarea Perhaps it was fitting how the Giants’ season ended, done in by a controversial check-swing call in Game 5 of the National League Division Series after their power-packed offense went missing against the Los Angeles Dodgers. After all, the […]

Read More

Saudi-owned Newcastle begin bold bid for ‘superpower’ status

A new era beckons for Newcastle on Sunday when a packed St James’ Park will witness the Magpies’ first match since a takeover led by the Saudi sovereign wealth fund took control of the club. Amanda Staveley, one of Newcastle’s new directors, says the consortium’s ambition is to turn the struggling club into Premier League […]

Read More